Healthcare Equipment and Supplies
Company Overview of Neuronetics, Inc.
Neuronetics, Inc., a medical device company, focuses on developing non-invasive therapies for treating psychiatric and neurological disorders using magnetic resonance imaging (MRI)-strength magnetic field pulses. It offers NeuroStar TMS Therapy, a transcranial magnetic stimulation device to treat patients with major depressive disorder. The company’s NeuroStar TMS Therapy uses a highly focused, pulsed magnetic field to stimulate function in brain regions that affects mood. Neuronetics, Inc. was founded in 2001 and is headquartered in Malvern, Pennsylvania.
3222 Phoenixville Pike
Malvern, PA 19355-1245
Founded in 2001
Key Executives for Neuronetics, Inc.
Chief Executive Officer and President
Vice President of Product Development & Operations
Vice President of New Business Development
Compensation as of Fiscal Year 2015.
Neuronetics, Inc. Key Developments
Neuronetics, Inc. Appoints Christopher Thatcher as President and Chief Executive Officer
Dec 1 14
Neuronetics, Inc. announced that Christopher Thatcher has joined the company as President and Chief Executive Officer. Mr. Thatcher has two decades of experience in general management and operational leadership in growing and transforming companies. Most recently Mr. Thatcher led the Reichert Technology Global Business Unit of Ametek, Inc. as its Divisional Vice President and Business Unit Manager. In this role, Mr. Thatcher was responsible for revitalizing its brand and expanding the business globally to achieve exponential revenue growth.
Neuronetics, Inc.'s NeuroStar TMS Therapy(R) Shows Promise as Effective Once-Monthly Maintenance Therapy in Patients with Major Depressive Disorder
May 5 14
Neuronetics, Inc. announced results from a new, dual-arm randomized pilot study that showed a trend toward symptomatic improvements with once-monthly TMS maintenance therapy in medication-free patients treated with NeuroStar TMS Therapy(R) for Major Depressive Disorder (MDD). Six weeks of acute NeuroStar TMS Therapy induced remission in 61.2% of all enrolled patients. At three months, 62.5% of medication-free patients randomized to once-monthly treatment with NeuroStar TMS Therapy maintained response as compared to 43.8% of patients who did not receive maintenance treatment. The complete findings will be presented at the 167th American Psychiatric Association Annual Meeting in New York City. In the study, medication-free patients with a diagnosis of unipolar, non-psychotic MDD, who had failed to receive benefit from prior antidepressant medication, were treated with six weeks of NeuroStar TMS Therapy; patients who met response criteria were randomized to either once- monthly maintenance TMS treatments or monthly observation. Patients in either cohort could receive TMS reintroduction for protocol-defined symptomatic worsening. The primary outcome was the proportion of patients without symptomatic worsening throughout the three months of the maintenance treatment phase.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 24, 2015
Most Searched Private Companies
Sponsored Financial Commentaries